Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

124.89USD
25 Jul 2016
Change (% chg)

-- (--)
Prev Close
$124.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,278,392
52-wk High
$126.07
52-wk Low
$81.79

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $343,913.09
Shares Outstanding(Mil.): 2,750.64
Dividend: 0.80
Yield (%): 2.56

Financials

  JNJ Industry Sector
P/E (TTM): 23.29 36.15 37.05
EPS (TTM): 5.37 -- --
ROI: -- 15.11 14.35
ROE: -- 16.17 15.56

J&J unit's former execs convicted of unapproved marketing

Two former executives of Acclarent Inc, a medical device company bought by Johnson & Johnson in 2010, were convicted on Wednesday by a U.S. jury on charges of promoting a product for an unapproved use.

Jul 20 2016

J&J unit's former executives convicted of unapproved marketing

Two former executives of Acclarent Inc, a medical device company bought by Johnson & Johnson in 2010, were convicted on Wednesday by a U.S. jury on charges of promoting a product for an unapproved use.

Jul 20 2016

J&J unit's former execs convicted of unapproved marketing

July 19 Two former executives of Acclarent Inc, a medical device company bought by Johnson & Johnson in 2010, were convicted on Wednesday by a U.S. jury on charges of promoting a product for an unapproved use.

Jul 20 2016

New MDL sought for cases over J&J talc powder and ovarian cancer

A federal judicial panel has been asked to consolidate nearly a dozen lawsuits filed in U.S. federal courts alleging Johnson & Johnson failed to warn women that using its talc-based powders for feminine hygiene could increase their risk of ovarian cancer.

Jul 20 2016

Johnson & Johnson raises 2016 forecast, shares touch record high

Johnson & Johnson on Tuesday raised its full-year 2016 sales and earnings forecasts and reported quarterly results that beat estimates, helped by strength in its prescription drugs business.

Jul 19 2016

UPDATE 4-Johnson & Johnson raises 2016 forecast, shares touch record high

July 19 Johnson & Johnson on Tuesday raised its full-year 2016 sales and earnings forecasts and reported quarterly results that beat estimates, helped by strength in its prescription drugs business.

Jul 19 2016

BRIEF-Johnson & Johnson posts Q2 earnings of $1.43/share

* Q2 earnings per share view $1.68 -- Thomson Reuters I/B/E/S

Jul 19 2016

J&J quarterly sales rise 3.9 pct

July 19 Diversified healthcare company Johnson & Johnson reported a 3.9 percent increase in second-quarter sales, helped by strength in its pharmaceuticals business.

Jul 19 2016

TPG to acquire surgical tools maker Beaver-Visitec

TPG Capital LP, one of the world's largest private equity firms, has agreed to acquire Beaver-Visitec International, a U.S. maker of tools used in eye surgery, from buyout firm RoundTable Capital Partners.

Jul 18 2016

TPG to acquire surgical tools maker Beaver-Visitec

July 18 TPG Capital LP, one of the world's largest private equity firms, has agreed to acquire Beaver-Visitec International, a U.S. maker of tools used in eye surgery, from buyout firm RoundTable Capital Partners.

Jul 18 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Wright Reports
$75.00
Provider : New Constructs, LLC
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.